An example of this was described by Rolfo et al. (2021) [131], who reported that ctDNA analysis enabled the detection of resistance mutations—such as EGFR T790M—in NSCLC patients, facilitating timely treatment modifications without requiring repeat biopsies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.